参考文献
[1] Eltzschig HK. Adenosine: an old drug newly discovered[J]. Anesthesiology, 2009, 111(4):904‑915. DOI: 10.1097/ALN.0b013e3181b060f2.
[2] Karmouty‑Quintana H, Xia Y, Blackburn MR. Adenosine signaling during acute and chronic disease states[J]. J Mol Med (Berl), 2013, 91(2):173‑181. DOI: 10.1007/s00109‑ 013‑0997‑1.
[3] Borea PA, Gessi S, Merighi S, et al. Pharmacology of adenosine receptors: the state of the art[J]. Physiol Rev, 2018, 98(3):1591‑1625. DOI: 10.1152/physrev.00049.2017.
[4] 中华医学会心血管病学分会. 冠状动脉微血管疾病诊断和治疗中国专家共识(2023版)[J]. 中华心血管病杂志, 2024, 52(5):460‑492. DOI:10.3760/cma.j.cn112148‑ 20231222‑00521.
[5] Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2020, 41(5):655‑720. DOI: 10.1093/eurheartj/ehz467.
[6] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J]. 中华心血管病杂志, 2019, 47(10):766‑783. DOI:10.3760/cma.j.issn.0253‑3758.2019.10.003.
[7] Steeds RP, Wheeler R, Bhattacharyya S, et al. Stress echocardiography in coronary artery disease: a practical guideline from the British Society of Echocardiography[J]. Echo Res Pract, 2019, 6(2):G17‑G33. DOI: 10.1530/ERP‑18‑0068.
[8] 中华医学会核医学分会, 中华医学会心血管病学分会. 核素心肌显像临床应用指南(2018)[J]. 中华心血管病杂志, 2019, 47(7):519‑527. DOI: 10.3760/cma.j.issn.0253‑ 3758.2019.07.003.
[9] Hayes ES. Adenosine receptors and cardiovascular disease: the adenosine‑1 receptor (A1) and A1 selective ligands[J]. Cardiovasc Toxicol, 2003, 3(1):71‑88. DOI: 10.1385/ct:3:1:71.
[10] Mubagwa K, Mullane K, Flameng W. Role of adenosine in the heart and circulation[J]. Cardiovasc Res, 1996, 32(5):797‑813.
[11] Ye H, Zhao J, Xu X, et al. Role of adenosine A2a receptor in cancers and autoimmune diseases[J]. Immun Inflamm Dis, 2023, 11(4):e826. DOI: 10.1002/iid3.826.
[12] Shryock JC, Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology[J]. Am J Cardiol, 1997, 79(12A):2‑10. DOI: 10.1016/s0002‑9149(97)00256‑7.
[13] Collis MG, Hourani SM. Adenosine receptor subtypes[J]. Trends Pharmacol Sci, 1993, 14(10):360‑366. DOI: 10.1016/0165‑6147(93)90094‑z.
[14] Dubey RK, Baruscotti I, Stiller R, et al. Adenosine, via A(2B) receptors, inhibits human (P‑SMC) progenitor smooth muscle cell growth[J]. Hypertension, 2020, 75(1):109‑118. DOI: 10.1161/HYPERTENSIONAHA.119.13698.
[15] Borea PA, Varani K, Vincenzi F, et al. The A3 adenosine receptor: history and perspectives[J]. Pharmacol Rev, 2015, 67(1):74‑102. DOI: 10.1124/pr.113.008540.
[16] Reiss AB, Grossfeld D, Kasselman LJ, et al. Adenosine and the cardiovascular system[J]. Am J Cardiovasc Drugs, 2019, 19(5):449‑464. DOI: 10.1007/s40256‑019‑00345‑5.
[17] Fredholm BB, Sollevi A. Cardiovascular effects of adenosine[J]. Clin Physiol, 1986, 6(1):1‑21. DOI: 10.1111/j.1475‑097x.1986.tb00139.x.
[18] Martin TW, Seaworth JF, Johns JP, et al. Comparison of adenosine, dipyridamole, and dobutamine in stress echocardiography[J]. Ann Intern Med, 1992, 116(3):190‑196. DOI: 10.7326/0003‑4819‑116‑3‑190.
[19] 吴碧君, 黄红艳, 周苏晋, 等. 三维斑点追踪技术结合腺苷负荷试验诊断早期冠心病的临床价值[J]. 中国全科医学, 2017, 20(18):2274‑2278. DOI: 10.3969/j.issn.1007‑ 9572.2017.18.023.
[20] 王俊香, 张雪梅, 程功, 等. 腺苷负荷心肌声学造影对冠心病稳定型心绞痛的诊断价值[J]. 实用心脑肺血管病杂志, 2022, 30(6):101‑104. DOI: 10.12114/j.issn.1008‑5971. 2022.00.126.
[21] Aggeli C, Christoforatou E, Giannopoulos G, et al. The diagnostic value of adenosine stress‑contrast echocardiography for diagnosis of coronary artery disease in hypertensive patients: comparison to Tl‑201 single‑photon emission computed tomography[J]. Am J Hypertens, 2007, 20(5):533‑538. DOI: 10.1016/j.amjhyper.2006.10.003.
[22] Hildick‑Smith DJ, Maryan R, Shapiro LM. Assessment of coronary flow reserve by adenosine transthoracic echocardiography: validation with intracoronary Doppler[J]. J Am Soc Echocardiogr, 2002, 15(9):984‑990. DOI: 10.1067/mje.2002.120982.
[23] Caiati C, Montaldo C, Zedda N, et al. Validation of a new noninvasive method (contrast‑enhanced transthoracic second harmonic echo Doppler) for the evaluation of coronary flow reserve: comparison with intracoronary Doppler flow wire[J]. J Am Coll Cardiol, 1999, 34(4):1193‑1200. DOI: 10.1016/s0735‑1097(99)00342‑3.
[24] 孙雪林, 胡欣, 金鹏飞. 腺苷负荷超声心动图在冠心病诊断中的评价研究[J]. 中国合理用药探索, 2022, 19(11):65‑71. DOI: 10.3969/j.issn.2096‑3327.2022.11.005.
[25] 浙江省核医学中心, 浙江省医学会核医学与放射医学防护分会质控学组. 浙江省99mTc‑MIBI SPECT心肌灌注显像检查规范及质量控制专家共识(2020版)[J]. 浙江医学, 2021, 43(2):117‑123,147. DOI: 10.12056/j.issn.1006‑2785.2021.43.2.2020-4231.
[26] Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons[J]. Circulation, 2012, 126(25):e354‑e471. DOI: 10.1161/CIR.0b013e318277d6a0.
[27] 李冬香, 李晓亭, 季林林. 腺苷负荷试验心肌灌注显像诊断冠心病的临床价值[J].中国医药指南, 2017, 15(28):94‑95. DOI:10.15912/j.cnki.gocm.2017.28.075.
[28] 韩宝华, 罗晓婷. 腺苷负荷心肌核素显像、心电图与心脏超声室壁运动对冠心病心肌缺血诊断价值比较分析[J]. 广西医科大学学报, 2017, 34(10):1495‑1497. DOI: 10.16190/j.cnki.45‑1211/r.2017.10.027.
[29] Tonet E, Pompei G, Faragasso E, et al. Coronary microvascular dysfunction: PET, CMR and CT assessment[J]. J Clin Med, 2021, 10(9):1848. DOI: 10.3390/jcm10091848.
[30] Schindler TH, Schelbert HR, Quercioli A, et al. Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health[J]. JACC Cardiovasc Imaging, 2010, 3(6):623‑640. DOI: 10.1016/j.jcmg.2010.04.007.
[31] Lanza GA, Camici PG, Galiuto L, et al. Methods to investigate coronary microvascular function in clinical practice[J]. J Cardiovasc Med (Hagerstown), 2013, 14(1):1‑18. DOI: 10.2459/JCM.0b013e328351680f.
[32] Schindler TH, Fearon WF, Pelletier‑Galarneau M, et al. Myocardial perfusion PET for the detection and reporting of coronary microvascular dysfunction: A JACC: Cardiovascular imaging expert panel statement[J]. JACC Cardiovasc Imaging, 2023, 16(4):536‑548. DOI: 10.1016/j.jcmg.2022.12.015.
[33] 赵慧, 李文豪, 程功, 等. 腺苷负荷与ATP负荷评估冠状动脉微血管疾病中的不良反应分析[J]. 中国全科医学, 2024, 27(17):2109‑2112. DOI: 10.12114/j.issn.1007‑9572. 2023.0526.
[34] 陈怡, 余成新, 李博. 腺苷负荷心肌灌注显像在冠心病中的研究进展[J]. 巴楚医学, 2022, 5(2):105‑108. DOI: 10.3969/j.issn.2096‑6113.2022.02.022.
[35] 中华医学会心血管病学分会影像学组, 中国医师协会放射医师分会心血管专业, 委员会. 无创性心血管影像学技术临床适用标准中国专家共识[J]. 中华心血管病杂志, 2020, 48(11):906‑921. DOI: 10.3760/cma.j.cn112148‑ 20200413‑00309.
[36] Greenwood JP, Motwani M, Maredia N, et al. Comparison of cardiovascular magnetic resonance and single‑photon emission computed tomography in women with suspected coronary artery disease from the Clinical Evaluation of Magnetic Resonance Imaging in Coronary Heart Disease (CE‑MARC) Trial[J]. Circulation, 2014, 129(10):1129‑1138. DOI: 10.1161/CIRCULATIONAHA.112.000071.
[37] Gulati A, Ismail TF, Ali A, et al. Microvascular dysfunction in dilated cardiomyopathy: A quantitative stress perfusion cardiovascular magnetic resonance study[J]. JACC Cardiovasc Imaging, 2019, 12(8 Pt 2):1699‑1708. DOI: 10.1016/j.jcmg.2018.10.032.
[38] Ong P, Safdar B, Seitz A, et al. Diagnosis of coronary microvascular dysfunction in the clinic[J]. Cardiovasc Res, 2020, 116(4):841‑855. DOI: 10.1093/cvr/cvz339.
[39] Koschade B, Young J, Richardson J, et al. Safety of adenosine stress perfusion cardiac magnetic resonance[J]. Heart Lung Circ, 2011,20(sup 2):S191.DOI:https://doi.org/10.1016/j.hlc.2011.05.472.
[40] 俞雅蓉, 于丽华, 代旭, 等. CT心肌灌注成像在缺血性心脏病诊断中的研究进展[J]. 医学综述, 2021, 27(16):3280‑3285. DOI: 10.3969/j.issn.1006‑2084.2021.16.029.
[41] Meinel FG, Pugliese F, Schoepf UJ, et al. Prognostic value of stress dynamic myocardial perfusion CT in a multicenter population with known or suspected coronary artery disease[J]. AJR Am J Roentgenol, 2017, 208(4):761‑769. DOI: 10.2214/AJR.16.16186.
[42] Hamon M, Geindreau D, Guittet L, et al. Additional diagnostic value of new CT imaging techniques for the functional assessment of coronary artery disease: a meta‑analysis[J]. Eur Radiol, 2019, 29(6):3044‑3061. DOI: 10.1007/s00330‑018‑5919‑8.
[43] Celeng C, Leiner T, Maurovich‑Horvat P, et al. Anatomical and functional computed tomography for diagnosing hemodynamically significant coronary artery disease: a meta‑analysis[J]. JACC Cardiovasc Imaging, 2019, 12(7 Pt 2):1316‑1325. DOI: 10.1016/j.jcmg.2018.07.022.
[44] Nous F, Geisler T, Kruk M, et al. Dynamic myocardial perfusion CT for the detection of hemodynamically significant coronary artery disease[J]. JACC Cardiovasc Imaging, 2022, 15(1):75‑87. DOI: 10.1016/j.jcmg.2021. 07.021.
[45] Ko BS, Cameron JD, Meredith IT, et al. Computed tomography stress myocardial perfusion imaging in patients considered for revascularization: a comparison with fractional flow reserve[J]. Eur Heart J, 2012, 33(1):67‑77. DOI: 10.1093/eurheartj/ehr268.
[46] Bechsgaard DF, Gustafsson I, Michelsen MM, et al. Evaluation of computed tomography myocardial perfusion in women with angina and no obstructive coronary artery disease[J]. Int J Cardiovasc Imaging, 2020, 36(2):367‑382. DOI: 10.1007/s10554‑019‑01723‑5.
[47] 李婧, 刘挨师. 负荷CT心肌灌注应用于冠状动脉微循环障碍评价的研究进展[J]. 中国CT和MRI杂志, 2023, 21(7):174‑176. DOI: 10.3969/j.issn.1672‑5131.2023.07.058.
[48] Mazur W, Bitar JN, Lechin M, et al. Coronary flow reserve may predict myocardial recovery after myocardial infarction in patients with TIMI grade 3 flow[J]. Am Heart J, 1998, 136(2):335‑344. DOI: 10.1053/hj.1998.v136.89905.
[49] Ferrari M, Schnell B, Werner GS, et al. Safety of deferring angioplasty in patients with normal coronary flow velocity reserve[J]. J Am Coll Cardiol, 1999, 33(1):82‑87. DOI: 10.1016/s0735‑1097(98)00552‑x.
[50] Rudzinski W, Waller AH, Rusovici A, et al. Comparison of efficacy and safety of intracoronary sodium nitroprusside and intravenous adenosine for assessing fractional flow reserve[J]. Catheter Cardiovasc Interv, 2013, 81(3):540‑544. DOI: 10.1002/ccd.24652.
[51] Toth G, De Bruyne B, Casselman F, et al. Fractional flow reserve‑guided versus angiography‑guided coronary artery bypass graft surgery[J]. Circulation, 2013, 128(13):1405‑1411. DOI: 10.1161/CIRCULATIONAHA.113.002740.
[52] Smits PC, Abdel‑Wahab M, Neumann FJ, et al. Fractional Flow Reserve‑Guided Multivessel Angioplasty in Myocardial Infarction[J]. N Engl J Med, 2017, 376(13):1234‑1244. DOI: 10.1056/NEJMoa1701067.
[53] Lee JM, Kim HK, Park KH, et al. Fractional flow reserve versus angiography‑guided strategy in acute myocardial infarction with multivessel disease: a randomized trial[J]. Eur Heart J, 2023, 44(6):473‑484. DOI: 10.1093/eurheartj/ehac763.
[54] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Eur Heart J, 2016, 37(38):2893‑2962. DOI: 10.1093/eurheartj/ehw210.
[55] Goette A, Kalman JM, Aguinaga L, et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication[J]. Heart Rhythm, 2017, 14(1):e3‑e40. DOI: 10.1016/j.hrthm.2016.05.028.
[56] January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society[J]. J Am Coll Cardiol, 2014, 64(21):e1‑e76. DOI: 10.1016/j.jacc.2014.03.022.
[57] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Europace, 2016, 18(11):1609‑1678. DOI: 10.1093/europace/euw295.
[58] Kuck KH, Brugada J, Fürnkranz A, et al. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation[J]. N Engl J Med, 2016, 374(23):2235‑2245. DOI: 10.1056/NEJMoa1602014.
[59] Macle L, Khairy P, Weerasooriya R, et al. Adenosine‑guided pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre, randomised superiority trial[J]. Lancet, 2015, 386(9994):672‑679. DOI: 10.1016/S0140‑6736(15)60026‑5.
[60] Iqbal M, Jena A, Park HS, et al. Value of adenosine test to reveal dormant conduction or adenosine‑induced atrial fibrillation after pulmonary vein isolation[J]. J Arrhythm, 2017, 33(6):602‑607. DOI: 10.1016/j.joa.2017.07.015.
[61] Wang N, Phan S, Kanagaratnam A, et al. Adenosine Testing After Atrial Fibrillation Ablation: Systematic Review and Meta‑Analysis[J]. Heart Lung Circ, 2018, 27(5):601‑610. DOI: 10.1016/j.hlc.2017.04.020.
[62] McLellan A, Kumar S, Smith C, et al. The role of adenosine challenge in catheter ablation for atrial fibrillation: A systematic review and meta‑analysis[J]. Int J Cardiol, 2017,236:253‑261. DOI: 10.1016/j.ijcard.2017.01.070.
[63] Orejarena LA, Vidaillet H Jr, DeStefano F, et al. Paroxysmal supraventricular tachycardia in the general population[J]. J Am Coll Cardiol, 1998, 31(1):150‑157. DOI: 10.1016/s0735‑1097(97)00422‑1.
[64] Porter MJ, Morton JB, Denman R, et al. Influence of age and gender on the mechanism of supraventricular tachycardia[J]. Heart Rhythm, 2004, 1(4):393‑396. DOI: 10.1016/j.hrthm.2004.05.007.
[65] 姚福梅, 王霞. 静脉腺苷和普罗帕酮转复室上性心动过速临床疗效评价[J]. 首都医药, 2005, 12(22):39‑40. DOI: 10.3969/j.issn.1005‑8257.2005.22.021.
[66] 国产腺苷与维拉帕米终止室上性心动过速试验组. 国产腺苷和维拉帕米终止室上性心动过速的临床研究[J]. 中华内科杂志, 2003, 42(11):773‑776. DOI: 10.3760/j.issn:0578‑1426.2003.11.009.
[67] Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society[J]. Circulation, 2016, 133(14):e506‑e574. DOI: 10.1161/CIR.0000000000000311.
[68] 何振伟, 黄建飞, 詹少卿, 等. 腺苷终止阵发性室上性心动过速的国内研究进展[J]. 中国药师, 2008, 11(4):399‑401. DOI: 10.3969/j.issn.1008‑049X.2008.04.013.
[69] Paul T, Pfammatter JP. Adenosine: an effective and safe antiarrhythmic drug in pediatrics[J]. Pediatr Cardiol, 1997, 18(2):118‑126. DOI: 10.1007/s002469900129.
[70] Lewis J, Arora G, Tudorascu DL, et al. Acute management of refractory and unstable pediatric supraventricular tachycardia[J]. J Pediatr, 2017,181:177‑182. DOI: 10.1016/j.jpeds.2016.10.051.
[71] Elkayam U, Goodwin TM. Adenosine therapy for supraventricular tachycardia during pregnancy[J]. Am J Cardiol, 1995, 75(7):521‑523. DOI: 10.1016/s0002‑9149(99)80597‑9.
[72] 杨秀秀, 陈韵岱. 无复流现象的预防与治疗[J]. 心肺血管病杂志, 2008, 27(1):55‑59. DOI: 10.3969/j.issn.1007‑5062.2008.01.019.
[73] Durante A, Camici PG. Novel insights into an "old" phenomenon: the no reflow[J]. Int J Cardiol, 2015,187:273‑280. DOI: 10.1016/j.ijcard.2015.03.359.
[74] Cenko E, Ricci B, Kedev S, et al. The no‑reflow phenomenon in the young and in the elderly[J]. Int J Cardiol, 2016,222:1122‑1128. DOI: 10.1016/j.ijcard.2016.07.209.
[75] 张彩芳. 冠心病患者经皮冠状动脉介入术中并发冠脉慢血流的影响因素分析[J]. 临床医学, 2023, 43(3):58‑60. DOI: 10.19528/j.issn.1003‑3548.2023.03.019.
[76] Scarpone M, Cenko E, Manfrini O. Coronary no‑reflow phenomenon in clinical practice[J]. Curr Pharm Des, 2018, 24(25):2927‑2933. DOI: 10.2174/1381612824666180702112536.
[77] Aparicio A, Cuevas J, Morís C, et al. Slow coronary blood flow: Pathogenesis and clinical implications[J]. Eur Cardiol, 2022, 17:e08. DOI: 10.15420/ecr.2021.46.
[78] Fuchs S, Kornowski R, Mehran R, et al. Prognostic value of cardiac troponin‑I levels following catheter‑based coronary interventions[J]. Am J Cardiol, 2000, 85(9):1077‑1082. DOI: 10.1016/s0002‑9149(00)00699‑8.
[79] Shahrivari M, Wise E, Resende M, et al. Peripheral blood cytokine levels after acute myocardial infarction: IL‑1β‑and IL‑6‑related impairment of bone marrow function[J]. Circ Res, 2017, 120(12):1947‑1957. DOI: 10.1161/CIRCRESAHA.116.309947.
[80] Norton ED, Jackson EK, Turner MB, et al. The effects of intravenous infusions of selective adenosine A1‑receptor and A2‑receptor agonists on myocardial reperfusion injury[J]. Am Heart J, 1992, 123(2):332‑338. DOI: 10.1016/0002‑8703(92)90643‑a.
[81] Niccoli G, Kharbanda RK, Crea F, et al. No‑reflow: again prevention is better than treatment[J]. Eur Heart J, 2010, 31(20):2449‑2455. DOI: 10.1093/eurheartj/ehq299.
[82] 侯飞, 李冬梅, 唐琳, 等. 山东省超药品说明书用药专家共识(2022版)系列——心血管药物超药品说明书用药专家共识[J]. 中国合理用药探索, 2022, 19(12):23‑29. DOI: 10.3969/j.issn.2096‑3327.2022.12.003.
[83] 赵红艳. 腺苷在急性心肌梗死再灌注中的作用[J]. 中国实用医药, 2009, 4(10):71‑72. DOI: 10.3969/j.issn.1673‑7555.2009.10.041.
[84] Niccoli G, Rigattieri S, De Vita MR, et al. Open‑label, randomized, placebo‑controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction: the REOPEN‑AMI study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction)[J]. JACC Cardiovasc Interv, 2013, 6(6):580‑589. DOI: 10.1016/j.jcin.2013.02.009.
[85] Zhang H, Tian NL, Hu ZY, et al. Three hours continuous injection of adenosine improved left ventricular function and infarct size in patients with ST‑segment elevation myocardial infarction[J]. Chin Med J (Engl), 2012, 125(10):1713‑1719.
[86] Hanna GP, Yhip P, Fujise K, et al. Intracoronary adenosine administered during rotational atherectomy of complex lesions in native coronary arteries reduces the incidence of no‑reflow phenomenon[J]. Catheter Cardiovasc Interv, 1999, 48(3):275‑278. DOI: 10.1002/(sici)1522‑726x(199911)48∶3<275::aid‑ccd8>3.0.co;2‑m.
[87] Ozdemir M, Cemri M, Yalçin R, et al. Use of intracoronary adenosine for the management of slow‑no‑reflow phenomenon during percutaneous interventions[J]. Catheter Cardiovasc Interv, 2001, 54(2):267‑268. DOI: 10.1002/ccd.1281.
[88] Ely SW, Mentzer RM Jr, Lasley RD, et al. Functional and metabolic evidence of enhanced myocardial tolerance to ischemia and reperfusion with adenosine[J]. J Thorac Cardiovasc Surg, 1985, 90(4):549‑556.
[89] Yellon DM, Baxter GF, Garcia‑Dorado D, et al. Ischaemic preconditioning: present position and future directions[J]. Cardiovasc Res, 1998, 37(1):21‑33. DOI: 10.1016/s0008‑6363(97)00214‑9.
[90] Downey JM, Cohen MV. Signal transduction in ischemic preconditioning[J]. Adv Exp Med Biol, 1997,430:39‑55. DOI: 10.1007/978‑1‑4615‑5959‑7_4.
[91] Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo‑controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial[J]. J Am Coll Cardiol, 1999, 34(6):1711‑1720. DOI: 10.1016/s0735‑1097(99)00418‑0.
[92] Ross AM, Gibbons RJ, Stone GW, et al. A randomized, double‑blinded, placebo‑controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD‑II)[J]. J Am Coll Cardiol, 2005, 45(11):1775‑1780. DOI: 10.1016/j.jacc.2005.02.061.
[93] Bulluck H, Sirker A, Loke YK, et al. Clinical benefit of adenosine as an adjunct to reperfusion in ST‑elevation myocardial infarction patients: An updated meta‑analysis of randomized controlled trials[J]. Int J Cardiol, 2016,202:228‑237. DOI: 10.1016/j.ijcard.2015.09.005.
[94] Polimeni A, De Rosa S, Sabatino J, et al. Impact of intracoronary adenosine administration during primary PCI: A meta‑analysis[J]. Int J Cardiol, 2016,203:1032‑1041. DOI: 10.1016/j.ijcard.2015.11.086.
[95] 中国生物医学工程学会体外循环分会, 侯晓彤. 2022年中国心血管外科手术和体外循环数据白皮书[J]. 中国体外循环杂志, 2023, 21(4):197‑200. DOI: 10.13498/j.cnki.chin.j.ecc.2023.04.2.
[96] Wei M, Kuukasjärvi P, Laurikka J, et al. Cardioprotective effect of adenosine pretreatment in coronary artery bypass grafting[J]. Chest, 2001, 120(3):860‑865. DOI: 10.1378/chest.120.3.860.
[97] Lee HT, LaFaro RJ, Reed GE. Pretreatment of human myocardium with adenosine during open heart surgery[J]. J Card Surg, 1995, 10(6):665‑676. DOI: 10.1111/j.1540‑8191.1995.tb00657.x.
[98] Mentzer RM Jr, Birjiniuk V, Khuri S, et al. Adenosine myocardial protection: preliminary results of a phase II clinical trial[J]. Ann Surg, 1999, 229(5):643‑649; discussion 649‑650. DOI: 10.1097/00000658‑199905000‑00006.
[99] Jakobsen Ø, Næsheim T, Aas KN, et al. Adenosine instead of supranormal potassium in cardioplegia: it is safe, efficient, and reduces the incidence of postoperative atrial fibrillation. A randomized clinical trial[J]. J Thorac Cardiovasc Surg, 2013, 145(3):812‑818. DOI: 10.1016/j.jtcvs.2012.07.058.
[100] 邢家林, 李蛟, 李蔚然, 等. 腺苷在婴幼儿体外循环心脏术中心肌保护作用的研究[J]. 中国体外循环杂志, 2012, 10(4):200‑202,211. DOI: 10.3969/j.issn.1672‑1403.2012.04.003.
[101] 袁海云, 夏旭, 胡宁东, 等. 腺苷对体外循环下风湿性心脏病患者的心肌保护作用[J]. 深圳中西医结合杂志, 2016, 26(13):122‑124. DOI: 10.16458/j.cnki.1007‑0893.2016.13.061.
[102] Liu R, Xing J, Miao N, et al. The myocardial protective effect of adenosine as an adjunct to intermittent blood cardioplegia during open heart surgery[J]. Eur J Cardiothorac Surg, 2009, 36(6):1018‑1023. DOI: 10.1016/j.ejcts.2009.06.033.